Novartis AG/Fr. NOVN
08:00
10:05
12:10
14:15
16:20
1D1W1MYTD1Y5YMAX
About Novartis AG
Novartis AG is a Swiss multinational pharmaceutical company headquartered in Basel, Switzerland. It operates primarily in the healthcare industry, focusing on the research, development, and manufacturing of a wide range of prescription medications targeting oncology, immunology, neuroscience, and cardiovascular diseases. Key products include Cosentyx (for psoriasis and arthritis) and Entresto (for heart failure). Founded in 1996 through the merger of Ciba-Geigy and Sandoz, Novartis has a significant geographic presence, with operations in over 100 countries. A key competitive strength of the company is its strong investment in research and development, which underpins its substantial portfolio of innovative therapies.
Ticker
Fr. NOVN
Sector
Primary listing
XSWX
Employees
75,883
Headquarters
Basel, Switzerland
Website
Novartis AG Metrics
BasicAdvanced
CHF 205B
18.11
CHF 5.89
0.44
CHF 3.50
3.28%
Price and volume
Market cap
CHF 205B
Beta
0.44
52-week high
CHF 108.18
52-week low
CHF 81.10
Average daily volume
2.9M
Dividend rate
CHF 3.50
Financial strength
Current ratio
0.881
Quick ratio
0.583
Long term debt to equity
54.161
Total debt to equity
71.554
Dividend payout ratio (TTM)
54.32%
Interest coverage (TTM)
18.35%
Profitability
EBITDA (TTM)
20,097.907
Gross margin (TTM)
76.25%
Net profit margin (TTM)
25.53%
Operating margin (TTM)
36.29%
Effective tax rate (TTM)
12.40%
Revenue per employee (TTM)
CHF 596,730
Management effectiveness
Return on assets (TTM)
12.13%
Return on equity (TTM)
32.62%
Valuation
Price to earnings (TTM)
18.108
Price to revenue (TTM)
4.588
Price to book
4.62
Price to tangible book (TTM)
-19.95
Price to free cash flow (TTM)
15.082
Free cash flow yield (TTM)
6.63%
Free cash flow per share (TTM)
7.067
Dividend yield (TTM)
3.28%
Forward dividend yield
3.28%
Growth
Revenue change (TTM)
12.88%
Earnings per share change (TTM)
-14.91%
3-year revenue growth (CAGR)
7.00%
10-year revenue growth (CAGR)
1.08%
3-year earnings per share growth (CAGR)
-9.39%
10-year earnings per share growth (CAGR)
-0.19%
3-year dividend per share growth (CAGR)
4.34%
10-year dividend per share growth (CAGR)
3.97%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Novartis AG stock?
Novartis AG (NOVN) has a market cap of Fr.205B as of December 10, 2025.
What is the P/E ratio for Novartis AG stock?
The price to earnings (P/E) ratio for Novartis AG (NOVN) stock is 18.11 as of December 10, 2025.
Does Novartis AG stock pay dividends?
Yes, the Novartis AG (NOVN) stock pays dividends to shareholders. As of December 10, 2025, the dividend rate is Fr.3.5 and the yield is 3.28%. Novartis AG has a payout ratio of 54.32% on a trailing twelve-month basis.
When is the next Novartis AG dividend payment date?
The next Novartis AG (NOVN) dividend payment date is unconfirmed.
What is the beta indicator for Novartis AG?
Novartis AG (NOVN) has a beta rating of 0.44. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.